Top Markets
Coin of the day
Orexo AB (publ) Orexo AB (publ)

Orexo AB (publ)

ORXOF
株式のランク #24996
Orexo AB (publ) functions as a specialized pharmaceutical company, focusing on... Orexo AB (publ) functions as a specialized pharmaceutical company, focusing on the innovation, advancement, and marketing of both conventional medicines and digital therapeutic solutions. Its commercial reach extends across the United States, Europe, and the United Kingdom. The firm's existing line of pharmaceutical products includes Zubsolv tablets, which are prescribed for addressing opioid dependence; Abstral, used to manage acute breakthrough pain in cancer patients; and Edluar, formulated for the brief treatment of insomnia. Looking to its future offerings, Orexo is actively progressing several developmental candidates: OX124, an emergency medication for naloxone rescue; OX125, an intervention for nalmefene rescue; OX640, a potential treatment for allergic reactions; and OX338, a sublingual ketorolac tablet designed for moderate to severe pain relief. Furthermore, the company is engaged in the OX-MPI program, which aims to tackle microvascular diseases often linked with chronic inflammatory conditions. Beyond traditional drugs, Orexo provides a selection of digital health therapies, such as deprexis, a program tailored for treating mild to severe depression; vorvida, targeted at alcohol use disorder; and modia, a digital tool for managing opioid use disorder. Established in 1994, Orexo AB (publ) operates from its primary corporate offices located in Uppsala, Sweden.
株価
$1.55
最終同期: 2026-08-19
時価総額
$54.45M
変化(1日)
0.00%
変化(1年)
-23.27%
SE
取引 Orexo AB (publ) (ORXOF)

カテゴリー

Orexo AB (publ)(ORXOF)の株式分割履歴
Orexo AB (publ)株(シンボル:ORXOF)は合計で0回の株式分割を実施しました。
最新の株式分割はAug 21, 2026に行われました。
Aug 21, 2026より前に購入されたORXOF株は、現在0ORXOF株に相当します。
株式分割一覧
株式分割 分割比率 累積分割比率
提供された日付のデータは十分ではありません。
類似企業または競合他社の株式分割